

received by NIH on or before December 26, 1997 will be considered.

ADDRESSES: Requests for a copy of these patents, inquiries, comments and other materials relating to the contemplated license should be directed to: Elaine F. Gese, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Blvd., Suite 325, Rockville, MD 20852; Telephone: (301) 496-7056, ext. 282; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: U.S. Patent No. 5,157,110 describes a synthetic protein which is capable of inhibiting the complement cascade by binding to the C4b component of complement, and thereby provides a method for controlling the complement cascade. U.S. Patent No. 5,187,268 describes the cloned gene encoding this protein. Complement inhibitors may be used in compositions to prevent complement mediated attack and injury to cells prior to or during transplantation, or to prevent transplant rejection. In addition, complement inhibitors may be used in developing products for allogeneic and xenogeneic transplantation.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 15, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-28381 Filed 10-24-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: IL-4 Pseudomonas Exotoxin Fusion Protein Therapeutics

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR § 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in USPA SN 06/911,227 (U.S. Patent 4,892,827) entitled, "Recombinant Pseudomonas Exotoxins: Construction of an Active Immunotoxin with Low Side Effects"; USPA SN 08/225,224 (U.S. Patent 5,635,599) entitled, "Circularly Permuted Ligands and Circularly Permuted Chimeric Molecules"; USPA SN 08/722,258 entitled, "Proteins Comprising Circularly Permuted Ligands"; and USPA SN 08/616,785 entitled, "Convection-Enhanced Drug Delivery", to Neurocrine Biosciences of San Diego, California. The patent rights in these inventions have been assigned to the United States of America.

The field of use would be limited to IL-4 pseudomonas exotoxin fusion protein therapeutics.

DATES: Only written comments and/or applications for a license which are received by NIH on or before January 26, 1998 will be considered.

ADDRESSES: Requests for copies of the subject issued patents and pending patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Steven Ferguson, Senior Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852. Telephone: (301) 496-7056, ext. 266; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the pending patent applications.

SUPPLEMENTARY INFORMATION: The present inventions relate to a fusion protein construct which is able to target malignant glial cells in the brain and potentially other malignant cells throughout the body which overexpress the IL-4 receptor protein. The construct has two parts; a targeting moiety and a toxin. The targeting moiety is the IL-4

cytokine while the toxin is a modified pseudomonas-exotoxin. The construct can be delivered to the brain using a convention-enhanced methodology to target and destroy cancerous cells.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S. 209 and 37 CFR § 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of the 35 U.S.C. 209 and 37 CFR § 404.7.

Applications for a license to the field of use described in this Notice will be treated as objections to the contemplated license. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 17, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-28380 Filed 10-24-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Institute of Environmental Health Sciences (NIEHS); Notice of Meeting To Discuss the Procedures and Activities of the National Toxicology Program (NTP) Center for the Evaluation of Alternative Toxicological Methods and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)

SUMMARY: Pursuant to Public Law 103-43, notice is hereby given of a public meeting sponsored by the NIEHS and the NTP, U.S. Public Health Service, to discuss the planned procedures and activities of a new NTP Center for the Evaluation of Alternative Toxicological Methods and the ICCVAM, and to receive comments from invited participants and the public to assist with future activities and priorities.

The meeting will be held in the Conference Center, Building 101, South Campus, NIEHS, 111 Alexander Drive, Research Triangle Park, North Carolina 27709, on November 7, 1997, from 8:45 a.m. to 4:00 p.m.

Background Information: Public Law 103-43 directed the NIEHS to develop and validate alternative methods that